CJC-1295 No DAC: Molecular Identity and the Limits of Borrowed Evidence

FDA’s 2024 scientific briefing distinguishes CJC-1295 and CJC-1295 DAC as different active moieties. That distinction matters when a product labeled No DAC cites research on long-acting CJC-1295. The names do not make the materials interchangeable. FDA identity discussion.

The first research question is therefore identity. Before asking how large or long a hormone response might be, establish which exact material the evidence concerns. This profile explains what the related studies show and why they cannot supply missing results for an unspecified No DAC preparation.

Start with the molecule

A useful record should let another reader connect the product description to the methods of the cited paper. If that connection is missing, leave it unresolved rather than filling it with a familiar alias.

What the long-acting human study actually tested

A 2006 study examined long-acting CJC-1295 in healthy adults and reported sustained increases in GH and IGF-I. It studied that preparation’s pharmacology, not a product identified only as No DAC. Original study.

The finding belongs to the tested material. It does not establish a No DAC half-life, administration interval or expected clinical benefit. Even when the broad research aim is similar, the exposure question must be answered for the actual molecule.

This is not a claim that the two forms must behave oppositely. It is a narrower conclusion: evidence for one cannot determine the other’s performance without an appropriate bridge. A directly matched study or a validated comparison would be needed to make that bridge credible.

Pulsatility does not settle the identity question

A separate 2006 study of long-acting CJC-1295 found preserved GH pulsatility alongside increased basal secretion. It did not test an unspecified No DAC product. Original secretion study.

A description such as natural pulses can be misleading if it implies that every aspect of the hormone pattern remained unchanged. Read pulse frequency, pulse size, baseline level and total exposure separately. None of those measurements identifies a different product by itself.

The appropriate comparison is between verified materials studied with compatible sampling methods. A marketing timetable and a published hormone curve are not equivalent evidence.

What an identity match should contain

This checklist is a way to evaluate documentation, not a claim that every listed product has supplied it. A missing field should remain a visible uncertainty. A high purity number does not automatically fill every identity field.

The molecular-identity guide explains how to avoid matching studies by familiar names alone. The purity guide explains the narrower meaning of an analytical percentage.

Hormone measurements and meaningful outcomes

An increase in GH or IGF-I would demonstrate a hormonal response under the conditions measured. It would not, by itself, quantify changes in strength, recovery, sleep, fat mass or long-term health.

For each promised outcome, look for the corresponding measurement. A strength claim needs a functional assessment. A fat-loss claim needs a suitable body-composition assessment. A sleep claim needs defined sleep outcomes. A safety claim needs systematic monitoring over an appropriate period.

The hormone-results guide provides a framework for keeping these claims separate. The distinction remains necessary even after the molecular identity is resolved.

What can reasonably be expected?

This appraisal does not assign a numerical response to an unspecified No DAC material. It also does not infer a human schedule from the long-acting studies. The unresolved material match prevents a reliable transfer of their magnitude or timing.

A useful future study would characterize the material, measure its exposure and response, and describe the participant population clearly. If the intended claim is clinical, it should include a meaningful clinical endpoint rather than stopping at a hormone marker.

Repeated measurements and appropriate controls would help distinguish a response from background variation. Follow-up would be needed before claiming a durable benefit. These are criteria for evaluating evidence, not predictions that a future study will be positive.

How the blend entries differ

The No DAC plus ipamorelin profile adds another question: what does the combination do beyond either verified ingredient? Identifying the CJC material is necessary, but it does not by itself answer the combination question.

The DAC plus ipamorelin entry concerns a differently labeled pairing. The two pages remain separate because a reader should not accidentally transfer a formulation-specific result across them.

For the related long-acting component, see CJC-1295 DAC. Its evidence should retain its own material and study context.

Frequently asked questions

Is No DAC simply another spelling of the long-acting study material?

Do not assume that. The identity distinction needs to be resolved explicitly before using the study as direct evidence.

Can a published DAC half-life set a No DAC schedule?

No. This review does not establish that transfer. Exposure must be matched to the actual preparation.

Does a changed hormone level prove better recovery?

It answers a hormone question. Recovery needs its own defined outcome and comparison.

What would improve this profile’s certainty?

A verified identity match and original studies of that exact form would allow a more specific assessment.

Sources and review scope

The FDA document is used for its dated scientific identity assessment, not as a statement of current compounding law. The two original human studies are related long-acting evidence. This selected appraisal does not establish direct No DAC clinical outcomes.